Healthcare, Pharma & Life Sciences

PTC Therapeutics Closes ST-920 Fabry Gene Therapy Acquisition

Warren, N.J. – September 22, 2026 -- PTC Therapeutics, Inc. (NASDAQ: PTCT) has completed its acquisition of ST-920, a BLA-stage, one-time AAV gene therapy for Fabry disease, from Sangamo Therapeutics, Inc.

PTC targets Q4 2026 completion of rolling BLA submission for accelerated approval

The company confirmed that a rolling Biologics License Application submission to the FDA seeking accelerated approval of ST-920, also known as isaralgagene civaparvovec, is expected to be completed in the fourth quarter of 2026.

BD Names Ex-Lenovo Executive Art Hu as Chief Digital Officer

Image
BD Names Ex-Lenovo Executive Art Hu as Chief Digital Officer

Franklin Lakes, N.J. – September 22, 2026 -- BD (Becton, Dickinson and Company), listed on the NYSE under BDX, has appointed Arthur (Art) Hu as executive vice president and chief information and digital officer, effective September 30.

Hu Joins BD From Lenovo's Solutions and Services Group

Hu departs Lenovo Group, where he served as senior vice president, global chief information officer and chief technology and delivery officer for the Solutions and Services Group. He brings more than 25 years of experience in global technology, digital and business transformation. Prior to Lenovo, Hu spent over a decade at McKinsey & Company advising organizations on technology, operations and strategy.

Appointment Follows Retirement of Longtime BD Technology Chief

Hu succeeds Denise Russell Fleming, who will retire from BD at the end of 2026.

AHN Offers Up to $110,000 Loan Repayment to Recruit CRNAs

Image
AHN Offers Up to $110,000 Loan Repayment to Recruit CRNAs

Pittsburgh – September 22, 2026 -- Allegheny Health Network (AHN) will pay up to $110,000 toward student loans for nurse anesthesia students who commit to joining the health system as Certified Registered Nurse Anesthetists (CRNAs), under a new national recruitment program launched in partnership with Boston-based fintech Clasp.

AHN structures payments across three years to lock in early-career commitments

Under the program, AHN will pay up to $20,000 toward eligible loans after 12 months of full-time employment, up to $30,000 after 24 months, and up to $60,000 after 36 months, with payments made directly to loan servicers through the Clasp platform. Employees retain every dollar contributed toward principal, with no claw-back provisions if they leave after milestones are met.

NYU Langone Names Rutika Mehta Director of Upper GI Oncology

Image
NYU Langone Names Rutika Mehta Director of Upper GI Oncology

New York – September 22, 2026 -- NYU Langone Health's Perlmutter Cancer Center has appointed Rutika Mehta, MD, MPH, as director of upper GI medical oncology, expanding its clinical and research programs for esophageal and stomach cancers.

Mehta brings a clinical trials portfolio built at two prior academic centers

Mehta joins from Weill Cornell Medicine, where she established an Upper GI Working Group to advance clinical and research collaboration. She previously helped build the Upper GI Malignancies Program at Moffitt Cancer Center in Tampa, Florida, developing a clinical trials portfolio that gave patients access to new treatment options.

NBBJ, Stanford's Dr. Schulman Partner to AI-Proof Hospital Design

San Francisco – September 22, 2026 -- Architecture firm NBBJ has partnered with Stanford physician and health economist Dr. Kevin Schulman to redesign hospital campuses for an era of AI-driven care, as health systems commit billions of dollars to facilities meant to operate for decades under uncertain technology trajectories.

Hospitals face multibillion-dollar bets on unpredictable care models

Health systems are currently planning large-scale campuses even as AI, automation and distributed care delivery make it difficult to forecast how medicine will be practiced by the time those buildings open. The partnership targets a specific gap: making long-term real estate investments flexible enough to adapt to care models that do not yet exist.

Clinical AI Firm Amigo Rebrands as Concurrence, Cites 10M Interactions

Image
Clinical AI Firm Amigo Rebrands as Concurrence, Cites 10M Interactions

NEW YORK – September 22, 2026 -- Amigo, a platform for deploying clinical AI, has rebranded as Concurrence, marking an expansion beyond its original scope into unified data infrastructure for health systems, biopharma companies, and public health organizations. The company says its platform has already driven over 10 million patient interactions.

Concurrence builds a unified data foundation called the Health World Model

The Health World Model consolidates institutional data into a single foundation that supplies full patient context to both AI systems and clinicians. AI-powered workflows built on top of this foundation are deployed across the care journey, covering patient intake, medication management, and clinical decision support, capturing patient interactions at what the company describes as an atomic level of detail.

Made Scientific Buys 85,000 Sq. Ft. Cell Therapy Plant from National Resilience

Image
Made Scientific Buys 85,000 Sq. Ft. Cell Therapy Plant from National Resilience

Princeton – September 22, 2026 -- Made Scientific, Inc. has acquired an 85,000 sq. ft. clinical-to-commercial cell therapy manufacturing facility in East Norriton, Pennsylvania, from National Resilience, closing the transaction on September 22, 2026. The purchase expands the company's U.S. East Coast footprint to approximately 145,000 sq. ft. and 15 qualified GMP manufacturing suites across New Jersey and Pennsylvania.

Operational site eliminates greenfield ramp-up delays

The East Norriton facility is operational on close, with its manufacturing team having executed 145 GMP batches to date across autologous and allogeneic programs, including CAR-T and B-cell therapies. Made Scientific said sponsors can begin onboarding programs immediately, targeting 2027 clinical and commercial supply.

Glacis Cedes Control of OVERT AI Verification Standard to CHAI, AIGovOps

Image
Glacis Cedes Control of OVERT AI Verification Standard to CHAI, AIGovOps

Seattle – September 22, 2026 -- Glacis Technologies has agreed to transfer stewardship of OVERT, its open technical specification for verifying AI safeguards at runtime, to the Coalition for Health AI (CHAI) and the AIGovOps Foundation.

Glacis relinquishes sole control of the specification it created

Under the agreement announced today, CHAI and AIGovOps will jointly oversee the OVERT standard once a separate commencement certificate signed by all three parties takes effect. Glacis, the Seattle-based company that developed OVERT, will initially maintain the specification and operate its registry, but will act only as a non-voting editor once stewardship transfers.

Forus Hits $3B Valuation on $150M Raise as NYSE Hosts UNGA Week

Image
Forus Hits $3B Valuation on $150M Raise as NYSE Hosts UNGA Week

NEW YORK – September 22, 2026 -- Forus, an AI-driven healthcare startup, has reached a $3 billion valuation after closing a $150 million Series C funding round earlier this month, CEO Sahir Jaggi confirmed during a NYSE Live broadcast tied to the trading floor's pre-market advisory.

Forus raises $150 million to link doctors, pharmacies and biopharma data

Jaggi said the capital will support the company's platform connecting physicians, pharmacies, payers and biopharmaceutical firms to accelerate access to new treatments for patients.

FDA Clears IDE for Mercy's Ovarian Cancer Blood Test Trial

Image
FDA Clears IDE for Mercy's Ovarian Cancer Blood Test Trial

Waltham, Mass. – September 22, 2026 -- The U.S. Food and Drug Administration has approved Mercy BioAnalytics' Investigational Device Exemption application for its Evident Ovarian Cancer Screening Test, clearing the way for the company's pivotal SOARA Clinical Validation Study pending Institutional Review Board sign-off.

FDA clears IDE application for Mercy's Evident Ovarian Cancer Screening Test

The approval permits Mercy to launch the prospective SOARA study -- Safety in Ovarian Cancer for Average-Risk Women, Analysis -- to evaluate the safety of the blood-based test in average-risk women. The IDE clearance does not constitute FDA approval or clearance of the Evident test itself, but authorizes the specified clinical investigation to proceed.